6533b871fe1ef96bd12d105c
RESEARCH PRODUCT
The potential of serum neurofilament as biomarker for multiple sclerosis
Eva HavrdovaStefan BittnerJiwon OhFrauke ZippMar Tintorésubject
Oncologymedicine.medical_specialtyTreatment responseMultiple SclerosisNeurofilamentFilaments citoplasmàticsDiseaseneurofilamentUpdatesNeurofilament ProteinsInternal medicinemedicineHumans:aminoácidos péptidos y proteínas::proteínas::aminoácidos péptidos y proteínas::proteínas::proteínas del tejido nervioso::proteínas de neurofilamentos [COMPUESTOS QUÍMICOS Y DROGAS]Longitudinal StudiesSubclinical disease:Diagnosis::Prognosis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Esclerosi múltiple - Imatgeria per ressonància magnètica:diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings]AcademicSubjects/SCI01870business.industrytherapy responseMultiple sclerosis:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]biomarkers:Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores]:Amino Acids Peptides and Proteins::Proteins::Amino Acids Peptides and Proteins::Proteins::Nerve Tissue Proteins::Neurofilament Proteins [CHEMICALS AND DRUGS]Prognosismedicine.diseaseEsclerosi múltiple - PrognosiMagnetic Resonance ImagingClinical trialEarly results:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Biomarker (medicine)AcademicSubjects/MED00310Neurology (clinical)businessdescription
Abstract Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients. Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis. There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g. relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years. In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerative damage in multiple sclerosis is less clear. However, early results from real-world cohorts and clinical trials using sNfL as a marker of treatment response in multiple sclerosis are encouraging. Importantly, clinical algorithms should now be developed that incorporate the routine use of sNfL to guide individualized clinical decision-making in people with multiple sclerosis, together with additional fluid biomarkers and clinical and MRI measures. Here, we propose specific clinical scenarios where implementing sNfL measures may be of utility, including, among others: initial diagnosis, first treatment choice, surveillance of subclinical disease activity and guidance of therapy selection.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-03-05 | Brain |